Loading
T cells engineered with a receptor that sees fragments of proteins inside the cancer cell, reaching targets CAR-T cannot.
Afamitresgene autoleucel (Tecelra) was the first approved TCR-T, for MAGE-A4+ HLA-A*02+ synovial sarcoma (2024, label expanded 2026). Letetresgene (NY-ESO-1) followed in trials. Neoantigen-specific TCR-T against KRAS G12D and TP53 hotspots (NCI Rosenberg) and PRAME-directed TCR-T (Immatics IMA203, phase 3 in melanoma) are the most watched.
Transgenic αβ TCR recognises a peptide-HLA complex; restricted to patients with the matching HLA allele.
Nothing in the corpus depends on this yet.
Dependencies are what this technology cannot be delivered without: manufacturing steps, instruments, software, upstream methods. See its full chain on the map.
Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.
Letetresgene autoleucel is a second engineered T-cell receptor therapy for sarcoma, targeting NY-ESO-1 in synovial sarcoma and myxoid/round cell liposarcoma; a BLA is expected by the end of 2026.
TAC01-CLDN18.2 is an experimental TCR-T cell therapy from Triumvira Immunologics in phase 2 trials, aimed at Claudin 18.2.
The first drug to improve survival in metastatic uveal melanoma, and the first TCR-based bispecific.
Query for this technology: (TITLE:"TCR-T" OR ABSTRACT:"TCR-T" OR TITLE:"T cell receptor therapy" OR ABSTRACT:"T cell receptor therapy" OR TITLE:"TCR-engineered T cells" OR ABSTRACT:"TCR-engineered T cells"). Results are unfiltered search hits about TCR-T cell therapy, not a curated reading list.
Shares Public cell-therapy foundries at cancer centres for academics and start-ups, Patrick Hwu, Steven A. Rosenberg, Hospital-exemption cell therapies at scale, backed by a shared registry.
Shares TCR therapeutics for non-HLA-A*02 patients, HLA-A*02:01 restriction, PRAME, HLA-A.
Shares Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma, Letetresgene autoleucel, Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma.
Shares Engineered immune surveillance: long-lived programmed immune cells that patrol for early cancer, QIMR Berghofer Medical Research Institute, Cell-therapy release and potency testing, Viral vector manufacturing (lentiviral, retroviral, AAV).
Shares Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM), Antibodies that see mutant KRAS and p53 fragments displayed on the cell surface, PRAME, Tebentafusp.
Shares IGNYTE-ESO, Afamitresgene autoleucel, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Sarcomas (soft tissue, bone, GIST).
Shares HLA-A*02:01 restriction, Afamitresgene autoleucel, HLA-A, Tebentafusp.
Shares Steven A. Rosenberg, SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma, Advanced melanoma (unresectable stage III and stage IV), Manufacturing cost and time for living and radioactive medicines.
Open-source projects that implement or serve this technology, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Reconstructs T-cell and B-cell receptor repertoires from bulk or single-cell RNA-seq of tumours.
An R package for exploring immune receptor repertoires, from clonality to diversity.
T-cell and B-cell receptor analysis integrated with scanpy for tumour immune repertoires.
Distance-based analysis of T-cell receptor repertoires from the Fred Hutch, for grouping receptors that recognise the same antigens.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/